Screener
Taysha Gene Therapies, Inc. TSHA Payments to Acquire in Process Research and Development
Payments to Acquire in Process Research and Development at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Deferred revenue | — | (2,302) |
| Net cash used in operating activities | (40,878) | (22,020) |
| Cash flows from investing activities | ||
| Purchase of research and development license | (3,000) | — |
| Purchase of property, plant and equipment | (24) | (378) |
| Other | — | 7 |
| Net cash used in investing activities | (3,024) | (371) |
| Cash flows from financing activities |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s payments to acquire in process research and development?
- Taysha Gene Therapies, Inc. (TSHA) reported payments to acquire in process research and development of $3M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s payments to acquire in process research and development changed year-over-year?
- Taysha Gene Therapies, Inc.'s payments to acquire in process research and development increased by 693.7% year-over-year, from $378K to $3M.
- What does payments to acquire in process research and development mean?
- Payments to Acquire in Process Research and Development
Ask your AI about Taysha Gene Therapies, Inc.'s payments to acquire in process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude